Product nameAnti-E2F1 antibody [EPR3818(3)] - ChIP Grade
See all E2F1 primary antibodies
DescriptionRabbit monoclonal [EPR3818(3)] to E2F1 - ChIP Grade
Tested applicationsSuitable for: ChIP, WB, ICC/IF, IP, Flow Cyt, IHC-Pmore details
Species reactivityReacts with: Mouse, Rat, Human
Synthetic peptide within Human E2F1 aa 350 to the C-terminus (Cysteine residue). The exact sequence is proprietary.
Database link: Q01094
- NIH 3T3, HeLa, HepG2, T47D, Human spleen and fetal muscle lysates; E2F1-DDDDK tag transfected 293T lysate; HepG2 cells. ChIP: Chromatin prepared from NIH/3T3 cells.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
Storage bufferpH: 7.20
Preservative: 0.01% Sodium azide
Constituents: 9% PBS, 40% Glycerol, 0.05% BSA, 50% Tissue culture supernatant
PurityTissue culture supernatant
- Anti-E2F1 antibody [EPR3818(3)] (Alexa Fluor® 647) (ab200850)
- Anti-E2F1 antibody [EPR3818(3)] (Alexa Fluor® 488) (ab201243)
- Anti-E2F1 antibody [EPR3818(3)] (Alexa Fluor® 594) (ab208077)
- Anti-E2F1 antibody [EPR3818(3)] (Alexa Fluor® 555) (ab208078)
- Anti-E2F1 antibody [EPR3818(3)] (Phycoerythrin) (ab208871)
- Anti-E2F1 antibody [EPR3818(3)] - BSA and Azide free (ab218527)
Our Abpromise guarantee covers the use of ab179445 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|ChIP||Use 5 µg for 25 µg of chromatin.|
|WB||1/1000 - 1/5000. Predicted molecular weight: 47 kDa.|
|ICC/IF||1/100 - 1/250.|
|IP||1/10 - 1/100.|
|Flow Cyt||1/10 - 1/100.
ab172730 - Rabbit monoclonal IgG, is suitable for use as an isotype control with this antibody.
|IHC-P||Use at an assay dependent concentration.|
FunctionTranscription activator that binds DNA cooperatively with dp proteins through the E2 recognition site, 5'-TTTC[CG]CGC-3' found in the promoter region of a number of genes whose products are involved in cell cycle regulation or in DNA replication. The DRTF1/E2F complex functions in the control of cell-cycle progression from G1 to S phase. E2F-1 binds preferentially RB1 protein, in a cell-cycle dependent manner. It can mediate both cell proliferation and p53-dependent apoptosis.
Sequence similaritiesBelongs to the E2F/DP family.
modificationsPhosphorylated by CDK2 and cyclin A-CDK2 in the S-phase.
Acetylation stimulates DNA-binding. Enhanced under stress conditions such as DNA damage and inhibited by retinoblastoma protein pRB. Regulated by KAP1/TRIM28 which recruits HDAC1 to E2F1 resulting in deacetylation. Acetylated by P/CAF/KAT2B.
- Information by UniProt
- Dmel\CG6376 antibody
- Dmel_CG6376 antibody
- drosE2F1 antibody
Chromatin was prepared from NIH/3T3 cells according to the Abcam X-ChIP protocol. Cells were fixed with 1% formaldehyde for 10 minutes. The ChIP was performed with 25µg of chromatin, 5µg of ab179445 (red), and 20µl of protein A/G sepharose beads slurry (10µl of sepharose A beads + 10µl of sepharose G beads). 5μg of rabbit normal IgG was added to the beads control (grey). The immunoprecipitated DNA was quantified by real time PCR (Sybr green approach).
PBS only lot tested
All lanes : Anti-E2F1 antibody [EPR3818(3)] - ChIP Grade (ab179445) at 1/1000 dilution
Lane 1 : NIH 3T3 lysate
Lane 2 : HeLa lysate
Lane 3 : HepG2 lysate
Lane 4 : T47D lysate
Lane 5 : Human spleen lysate
Lane 6 : Human fetal muscle lysate
Lysates/proteins at 10 µg per lane.
Predicted band size: 47 kDa
Western blot analysis on immunoprecipitation pellet from NIH 3T3 cell lysate immunoprecipitated using ab179445 at 1/10 dilution.
Immunohistochemical analysis of breast samples, labeling E2F1 with ab179445.
Immunofluorescent analysis of HepG2 cells labeling E2F1 with ab179445 at 1/100 dilution.
Flow cytometric analysis of permeabilized Hela cells using anti-E2F1 RabMAb (red) (ab179445) or a rabbit IgG (negative) (green)
This product has been referenced in:
- Fang E et al. Valproic acid suppresses Warburg effect and tumor progression in neuroblastoma. Biochem Biophys Res Commun 508:9-16 (2019). Read more (PubMed: 30466785) »
- Ji W et al. Combined Androgen receptor blockade overcomes the resistance of breast cancer cells to palbociclib. Int J Biol Sci 15:522-532 (2019). Read more (PubMed: 30745839) »